National Center for Complementary & Integrative Health; Notice of Closed Meeting, 90300 [2024-26562]
Download as PDF
<![CDATA[
khammond on DSKJM1Z7X2PROD with NOTICES
90300
Federal Register / Vol. 89, No. 221 / Friday, November 15, 2024 / Notices
not promiscuous kinase inhibitors. The
subject kinase inhibitors have broad
potential commercial applicability’s for
cancer, immune suppression,
preventing organ rejection, treating
diabetic neuropathic pain, malaria, or
protozoa infection. To date, there are no
approved therapeutics targeting
DNAJB1–PRKCA, an oncogenic gene
fusion, which is ubiquitously and
exclusively detected in the tumors of
patients with ultra-rare fibrolamellar
hepatocellular carcinoma FLHCC.
This Notice is in accordance with 35
U.S.C. 209 and 37 CFR part 404.
NIH Reference Number: E–044–2022.
Related Technologies: E–202–2023
and E–162–2024.
Product Type: Therapeutic.
Therapeutic Area(s): Oncology,
Infectious Disease, Rare/Neglected
Diseases.
Potential Commercial Applications:
• Gastric cancer.
• Ultra-rare adolescent liver cancer.
• Solid cancers susceptible to kinase
inhibitors.
• Cushing’s Disease.
• Transplantation.
• Diabetic neuropathic pain.
• Malaria.
• Protozoa infection.
Competitive Advantages:
• Applicability to numerous
clinically relevant kinases, including:
Æ Oncogenic gene fusion DNAJB1–
PRKACA (PKADJ).
Æ Wild type protein kinase A (PKA).
Æ Protein kinase G (PKG).
Æ Ccdc2-like kinases (CLK) 1 and 2.
Æ DYRK family of kinases.
• Applicable to a range of kinases, but
are not promiscuous kinase inhibitors.
• Broad potential commercial
applicability for several blockbuster
indications including:
Æ cancer, immune suppression,
transplantation, diabetic neuropathic
pain, malaria, and protozoa infection.
• No approved therapeutics targeting
DNAJB1–PRKCA.
Publications:
• O’Keefe BR, et al. Biochemical
Discovery, Intracellular Evaluation, and
Crystallographic Characterization of
Synthetic and Natural Product
Adenosine 3′,5′-Cyclic MonophosphateDependent Protein Kinase A (PKA)
Inhibitors. PMID: 37082750, https://
pubmed.ncbi.nlm.nih.gov/37082750/.
• O’Keefe BR, et al. Discovery and
Synthesis of a Naturally Derived Protein
Kinase Inhibitor that Selectively Inhibits
Distinct Classes of Serine/Threonine
Kinases. PMID: 37843072, https://
pubmed.ncbi.nlm.nih.gov/37843072/.
Patent Status:
• E–044–2022: PCT/US2023/070304.
• E–202–2023: PCT/US2024/038376.
VerDate Sep<11>2014
16:11 Nov 14, 2024
Jkt 265001
• E–162–2024: 63/672,577.
Development Stage: Pre-clinical (in
vivo validation).
Dated: November 12, 2024.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2024–26663 Filed 11–14–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government Owned Inventions
Available for Licensing or
Collaboration: Improved Methods for
Cryopreservation of Cells, Tissues,
and Organs
AGENCY:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Center for Complementary &
Integrative Health; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Complementary and Integrative Health
Special Emphasis Panel; NCCIH Conference
Grant (R13 Clinical Trial Not Allowed).
Date: December 10, 2024
Time: 2:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Center for
Complementary and Integrative, Democracy
II, 6707 Democracy Blvd., Bethesda, MD
20892.
Meeting Format: Virtual Meeting.
Contact Person: Michael E. Authement,
Ph.D., Scientific Review Officer, Office of
Scientific Review, Division of Extramural
Activities, 6707 Democracy Boulevard,
Bethesda, MD 20817, michael.authement@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.213, Research and Training
in Complementary and Alternative Medicine,
National Institutes of Health, HHS)
Dated: November 8, 2024.
David W. Freeman,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
[FR Doc. 2024–26562 Filed 11–14–24; 8:45 am]
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
ACTION:
Notice.
The National Eye Institute
(NEI), an institute of the National
Institutes of Health (NIH), Department
of Health and Human Services (HHS), is
giving notice of licensing and/or
collaboration opportunities for the
inventions listed below, which are
owned by an agency of the U.S.
Government and are available for
licensing and/or collaboration to
achieve expeditious commercialization
of results of federally-funded research
and development.
FOR FURTHER INFORMATION CONTACT:
Inquiries related to these licensing and/
or collaboration opportunities should be
directed to: Hiba Alsaffar, Ph.D.,
Technology Transfer Manager, NCI,
Technology Transfer Center, Email:
hiba.alsaffar@nih.gov or Phone: 240–
276–7489.
SUPPLEMENTARY INFORMATION:
Researchers at the NEI seek licensing
and/or co-development research
collaborations for improved methods of
cryopreservation of cells, tissues, and
organs via FOXO1 activation. The
cornea is a critical part of the eye that
helps prevent debris from entering and
refracts light for proper vision. Corneal
disorders such as keratoconus, Fuchs
dystrophy, and infectious keratitis
require corneal transplantation to
restore vision. Approximately 185,000
corneal transplants are performed
annually worldwide to treat corneal
disorders. Corneas for those transplants
are supplied by donor eyes that are
stored at eye banks in select countries.
Currently, Optisol-GSTM is the corneal
preservation solution that is most
widely used to store donated corneas at
eye banks. Per NEI guidelines, corneas
preserved in Optisol-GSTM have a 12day shelf life. With the high demand for
corneal transplantations worldwide, a
12-day shelf life cannot meet the
requirement for long term cryogenic
storage of corneas at large eye banks.
Scientists at the NEI have developed
improved methods for cryopreservation
of cells, tissues, and organs (with focus
of corneal tissue/cells) that increases
SUMMARY:
National Institutes of Health
BILLING CODE 4140–01–P
National Institutes of Health,
HHS.
E:\FR\FM\15NON1.SGM
15NON1
]]>Agencies
[Federal Register Volume 89, Number 221 (Friday, November 15, 2024)]
[Notices]
[Page 90300]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-26562]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Center for Complementary & Integrative Health; Notice of
Closed Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Center for Complementary and
Integrative Health Special Emphasis Panel; NCCIH Conference Grant
(R13 Clinical Trial Not Allowed).
Date: December 10, 2024
Time: 2:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Address: National Center for Complementary and Integrative,
Democracy II, 6707 Democracy Blvd., Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Michael E. Authement, Ph.D., Scientific Review
Officer, Office of Scientific Review, Division of Extramural
Activities, 6707 Democracy Boulevard, Bethesda, MD 20817,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.213,
Research and Training in Complementary and Alternative Medicine,
National Institutes of Health, HHS)
Dated: November 8, 2024.
David W. Freeman,
Supervisory Program Analyst, Office of Federal Advisory Committee
Policy.
[FR Doc. 2024-26562 Filed 11-14-24; 8:45 am]
BILLING CODE 4140-01-P
